Liposomal Formulation to Increase Stability and Prolong Antineuropathic Activity of Verbascoside

Abstract

Verbascoside (acteoside) possesses various pharmacological properties for human health, including antioxidant, anti-inflammatory, and antineoplastic properties in addition to numerous wound healing and neuroprotective properties, with an excellent and well-known safety profile. However, its poor chemical stability, due to hydrolysis, limits its use in the clinic. To overcome these limitations, we prepared unilamellar liposomal formulations of verbascoside for parenteral administration.

Two formulations were prepared: V-L1 and V-L2, where V-L2 contains phospholipid and cholesterol about 4 times higher than the V-L1 sample, and about 2 times higher than verbascoside. The mean particle size of the liposomes prepared was found to be around 120 nm with a polydispersity index < 0.2. Encapsulation efficacy resulted in 30 %. A total of 82.28 ± 1.79 % of verbascoside was released from the liposomes within 24 hours. Liposomes ameliorate the stability of verbascoside by preventing its hydrolysis.

The optimized drug delivery formulation was tested in the paw pressure test in two animal models of neuropathic pain: a peripheral mononeuropathy was produced either by a chronic constriction injury of the sciatic nerve or by an intra-articular injection of sodium monoiodoacetate. The performance of the liposomal formulation was compared with that of the free drug.

For evaluating the paw pressure test in chronic constriction injury rats, a liposomal formulation administered i. p. at the dosage of 100 mg/kg showed a longer lasting antihyperalgesic effect in comparison with a 100-mg/kg verbascoside saline solution, as well as in the sodium monoiodoacetate models. The effect appeared 15 min after administration and persisted for up to 60 min.

Key words

verbascoside-loaded unilamellar liposomes - prolonged activity - prolonged release - antineurophatic activity - in vivo study

^* These authors contributed equally to this work.

• References

• 1 Harvey AL, Clark RL, Mackay SP, Johnston BF. Current strategies for drug discovery through natural products. Expert Opin Drug Discov 2010; 5: 559-568
• 2 Kumari A, Kumar V, Yadav SK. Nanotechnology: a tool to enhance therapeutic values of natural plant products. Trends Med Res 2012; 7: 34-42
• 3 Isacchi B, Iacopi R, Bergonzi MC, Ghelardini C, Galeotti N, Norcini M, Vivoli E, Vincieri FF, Bilia AR. Antihyperalgesic activity of verbascoside in two models of neuropathic pain. J Pharm Pharmacol 2011; 63: 594-601
• 4 Nakamura T, Okuyama E, Tsukada A, Yamazaki M, Satake M, Nishibe S, Deyama T, Moriya A, Maruno M, Nishimura H. Acteoside as analgesic principle of Cedron (Lippia triphylla) Peruvian medicinal plant. Chem Pharm Bull 1997; 45: 499-504
• 5 Calvo MI. Anti-inflammatory and analgesic activity of the topical preparation of Verbena officinalis L. J Ethnopharmacol 2006; 107: 380-382
• 6 Backhouse N, Delporte C, Apablaza C, Farías M, Goïty L, Arrau S, Negrete R, Castro C, Miranda H. Antinociceptive activity of Buddleja globosa (matico) in several models of pain. J Ethnopharmacol 2008; 119: 160-165
• 7 Lau CW, Chen ZY, Wong CM, Yao XQ, He ZD, Xu HX, Huang Y. Attenuated endothelium-mediated relaxation by acteoside in rat aorta: Role of endothelial [Ca²⁺] and nitric oxide/cyclic GMP pathway. Life Sci 2004; 75: 1149-1157
• 8 Penido C, Costa KA, Futuro DO, Paiva SR, Kaplan MA, Figueiredo MR, Henriques MG. Anti-inflammatory and anti-ulcerogenic properties of Stachytarpheta cayennensis (L.C. Rich) Valh. J Ethnopharmacol 2006; 104: 225-233
• 9 Korkina LG, Mikhalchik E, Suprun MV, Pastore S, Dal Toso R. Molecular mechanisms underlying wound healing and anti-inflammatory properties of naturally occurring biotecnologically produced phenylpropanoid glycosides. Cell Mol Biol (Noisy-le-grand) 2007; 30: 84-91
• 10 Hausmann M, Obermeier F, Paper DH, Balan K, Dunger N, Menzel K, Falk W, Schoelmerich J, Herfarth H, Rogler G. In vivo treatment with herbal phenylethanoid acteoside ameliorates intestinal inflammation in dextran sulphate sodium-induced colitis. Clin Exp Immunol 2007; 148: 373-381
• 11 Fleer H, Verspohl EJ. Antispasmodic activity of an extract from Plantago lanceolata L. and some isolated compounds. Phytomedicine 2007; 14: 409-415
• 12 Lee KW, Kim HJ, Lee YS, Park HJ, Choi JW, Ha J, Lee KT. Acteoside inhibits human promyelocytic HL-60 leukemia cell proliferation via inducing cell cycle arrest at G0/G1 phase and differentiation into monocyte. Carcinogenesis 2007; 28: 1928-1936
• 13 Akbay P, Calis I, Undeger U, Basaran N, Basaran AA. In vitro immunomodulatory activity of verbascoside from Nepetya ucrainica L. Phytother Res 2002; 16: 593-595
• 14 Lee JY, Woo ER, Kang KW. Inhibition of lipopolysaccharide-inducible nitric oxide synthase expression by acteoside through blocking of AP-1 activation. J Ethnopharmacol 2005; 97: 561-566
• 15 Avila Acevedo JG, Castañeda CMC, Benitez FJC, Durán DA, Barroso VR, Martínez CG, Muñoz LJL, Martínez CA, Romo de Vivar A. Photoprotective activity of Buddleja scordioides . Fitoterapia 2005; 76: 301-309
• 16 Bilia AR, Giomi M, Innocenti M, Gallori S, Vincieri FF. HPLC/DAD/ESI-MS analysis of the constituents of aqueous preparations of verbena and lemon verbena and evaluation of the antioxidant activity. J Pharm Biomed Anal 2008; 46: 463-470
• 17 Koltzenburg M. Painful neuropathies. Curr Opin Neurol 1998; 11: 515-521
• 18 Leighton GE, Hill RG, Hughes J. Intrathecal injection of an opioid agonist produces hyperalgesia in the guinea pig. Eur J Pharmacol 1988; 157: 241-242
• 19 Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988; 33: 87-107
• 20 Guingamp C, Gegout-Pottie P, Philippe L, Terlain B, Netter P, Gillet P. Mono-iodoacetate-induced experimental osteoarthritis: a dose-response study of loss of mobility, morphology, and biochemistry. Arthritis Rheum 1997; 40: 1670-1679
• 21 Malik NSA, Bradford JM. Recovery and stability of oleuropein and other phenolic compounds during extraction and processing of olive (Olea europaea L.) leaves. J Food Agric Environ 2008; 6: 8-13
• 22 Monfardini C, Veronese FM. Stabilization of substances in circulation. Bioconjug Chem 1998; 9: 418-450
• 23 Sinico C, Caddeo C, Valenti D, Fadda AM, Bilia AR, Vincieri FF. Liposomes as carriers for verbascoside: stability and skin permeation studies. J Liposome Res 2008; 18: 83-90
• 24 Chung H, Chim TW, Kwon M, Kwon IC, Jeong SY. Oil components modulate physical characteristics and function of the natural oil emulsions as drug or gene delivery system. J Control Release 2001; 71: 339-350
• 25 Ulrich AS. Biophysical aspects of using liposomes as delivery vehicles. Biosci Rep 2002; 22: 129-150
• 26 Cilliers JJL, Singleton VL. Autoxidative phenolic ring opening under alkaline conditions as a model for natural polyphenols in food. J Agric Food Chem 1990; 38: 1797-1798
• 27 Pierpoint WS. The enzymic oxidation of chlorogenic acid and some reactions of the quinone produced. Biochem J 1966; 98: 567-580
• 28 Kraft JC, Freeling JP, Wang Z, Ho RJY. Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J Pharm Sci 2014; 103: 29-52
• 29 Chen Y, Minh le V, Liu J, Angelov B, Drechsler M, Garamus VM, Willumeit-Römer R, Zou A. Baicalin loaded in folate-PEG modified liposomes for enhanced stability and tumor targeting. Colloids Surf B Biointerfaces 2016; 140: 74-82
• 30 Isacchi B, Arrigucci S, la Marca G, Bergonzi MC, Vannucchi MG, Novelli A, Bilia AR. Conventional and long-circulating liposomes of artemisinin: preparation, characterisation and pharmacokinetic profile in mice. J Liposome Res 2011; 21: 237-244
• 31 Eloy JO, Petrilli R, Topan JF, Ribeirov AHM, Abriata BJP, Chesca DL, Serafini LN, Tiezzi DG, Lee RJ, Marchetti JM. Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy. Colloids Surf B Biointerfaces 2016; 141: 74-82
• 32 Coimbra M, Isacchi B, van Bloois L, Torano JS, Ket A, Wu X, Broere F, Metselaar JM, Rijcken CJF, Storm G, Bila AR, Schiffelers RM. Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes. Int J Pharm 2011; 416: 433-442
• 33 Isacchi B, Fabbri V, Galeotti N, Bergonzi MC, Karioti A, Ghelardini C, Vannucchi MG, Bilia AR. Salvianolic acid B and its liposomal formulations: Anti-hyperalgesic activity in the treatment of neuropathic pain. Eur J Pharm Sci 2011; 44: 552-558
• 34 Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965; 13: 238-252
• 35 McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C. Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 2010; 160: 1573-1576
• 36 Leighton GE, Hill RG, Hughes J. Intrathecal injection of a kappa opioid agonist produces hyperalgesia in the guinea pig. Eur J Pharmacol 1988; 157: 241-242